Search Results for: Oxygen therapy apparatus
meeting with the fda. in september the company announced that it was making preparations for another phase iii clinical trial (intended to be named stride- ) to overcome the fda's concerns. [ ] the takeover by pfizer resulted in a reconfiguration and extension of these plans, to include combination therapy
"sitaxsentan therapy for pulmonary arterial hypertension". american journal of respiratory and critical care medicine. ( ): – . doi : /rccm. - oc . pmid . ^ a b citing liver damage, pfizer withdraws thelin , associated press, december , ^ girgis, re; frost, ae; hill, ns; horn, em; langleben, d; mclaughlin...
https://en.wikipedia.org/wiki/Sitaxentan